Matches 1 - 50 out of 181 1 2 3 4 >


Match Document Document Title
US20150118287 SYSTEMIC DELIVERY AND REGULATED EXPRESSION OF PARACRINE GENES FOR CARDIOVASCULAR DISEASES AND OTHER CONDITIONS  
In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition...
US20130225485 Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders  
Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the...
US20110263491 COMPOSITIONS AND METHODS FOR THE CONTROL, PREVENTION AND TREATMENT OF OBESITY AND EATING DISORDERS  
Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the...
US20130261051 Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals  
The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof,...
US20120219616 LIPOSOMAL REDUCED GLUTATHIONE AND l-ARGININE, INCLUDING WITH OTHER INGREDIENT(S), CAPABLE OF MULTIPATH ADMINISTRATION FOR REVERSAL AND PREVENTION OF OBESITY AND FOR MITOCHONDRIAL BIOGENESIS  
The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals...
US20110046047 Bone Morphogenetic Proteins for Appetite Control  
Methods of decreasing appetite for food intake by administering bone morphogenetic proteins (BMPs), e.g., BMP7, or agonists/peptidomimetics thereof.
US20110217380 PROTEINS THAT STIMULATE THE SECRETION OF SATIETY HORMONES  
The invention is in the field of weight management, in particular in the field of weight management by influencing the mechanisms of body-weight regulation. Intact pea protein and intact wheat...
US20140141100 Compounds and Methods for Appetite Suppression and Weight Control  
Disclosed is a method of treating obesity, reducing weight, preventing weight gain, and/or suppressing appetite in a subject in need thereof by administering topically a pharmaceutical compound...
US20110268795 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, prediabetic symptoms, insulin resistance and related disease states and conditions  
The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release...
US20110230399 Methods for Treating Obesity Related Disease  
The present invention relates to methods and products for the treatment of obesity. The invention discloses a method of treating obesity related disease in a mammal in need of such treatment...
US20130072445 DEVELOPMENT OF C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS  
The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the...
US20110152202 DEVELOPMENT OF C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS  
The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the...
US20120115776 ADIPONECTIN-CONTAINING EATING BEHAVIOR CONTROL AGENT FOR ORAL ADMINISTRATION  
Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is...
US20140186287 INGESTIBLE FORMULATIONS FOR TRANSIENT, NONINVASIVE REDUCTION OF GASTRIC VOLUME  
Provided are ingestible polymeric formulations and oral dosage forms for the reduction of gastric volume in the treatment of overweight and obese patients. The formulation includes an...
US20130177647 METHODS FOR MANIPULATING SATIETY  
Various embodiments of the invention disclosed herein include methods of inducing satiety a mammal in need thereof. Also disclosed are methods of inducing satiety in an obese mammal. Additionally...
US20150183861 METHOD FOR MODULATING APPETITE  
The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating...
US20130324462 Method of Reducing The Effects of Chemotherapy Using Flagellin Related Polypeptides  
The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described.
US20150045292 METHODS AND COMPOSITION FOR INDUCING SATIETY  
A flowable or spoonable medicament, food, food ingredient or food supplement is useful for inducing satiety. It comprises a protein and a methylcellulose (MC), wherein the weight ratio...
US20140308369 DIETARY PRODUCT INTENDED TO REDUCE VISCERAL FAT DURING THE PRE-OPERATIVE PHASE PRIOR TO BARIATRIC SURGERY  
An orally administered dietary product intended to reduce an obese person's visceral fat during the pre-operative phase prior to bariatric surgery, the product includes in particular a mixture of:...
US20110021420 MODIFICATION OF FEEDING BEHAVIOUR  
The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food...
US20130023465 Use of Human Chorionic Gonadotropin (hCG) by Oral-Sublingual or Injectable Route as an Appetite-Suppressant Agent.  
Use of Human Chorionic Gonadotropin (hCG) by oral-sublingual or injectable route for the treatment of several food disorders, as an appetite-suppressant agent, food compulsiveness as well as all...
US20130225486 CYSTEINE AND FOOD INTAKE  
The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional...
US20130324461 METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY  
The invention includes methods of treating, preventing, or limiting obesity or weight gain, or reducing or suppressing appetite, by the administration of A2A adenosine receptor pathway agonists....
US20150072925 Methods For Weight Loss And Ketogenic Compositions  
The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates. The composition...
US20130045915 METHOD FOR WEIGHT LOSS AND KETOGENIC COMPOSITIONS  
The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates. The composition...
US20140057838 OSTEOBLAST-EXPRESSED LIPOCALIN 2 REGULATES GLUCOSE METABOLISM  
Diseases including diabetes, metabolic syndrome, and obesity or obesity-related diseases are due to impairment in glucose metabolism. The skeleton has been shown to regulate energy metabolism and...
US20100323955 METHODS FOR TREATING OBESITY AND OBESITY RELATED DISEASES AND DISORDERS  
Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents...
US20120064039 Use of Guanylyl Cyclase C Agonists to Suppress Appetite  
Compositions comprising a guanylyl cyclase C agonist formulated for sustained specific release of an amount effective to suppress appetite when administered orally to an individual are disclosed....
US20150182597 COMPOSITIONS COMPRISING HYALURONIC ACID AND DERMATAN SULPHATE FOR THE TREATMENT OF BEING OVERWEIGHT AND OBESITY  
The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes,...
US20150011468 USES OF CASEIN COMPOSITIONS  
Casein compositions for increasing the rate of gastric emptying following ingestion of the composition, increasing the digestibility of a protein composition, or increasing the rate of delivery of...
US20150024066 METHODS FOR PREVENTING OR TREATING EXCESS WEIGHT USING OXYNTOMODULIN  
Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.
US20150025001 FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME  
The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically,...
US20110039768 FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME,  
The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically,...
US20050171003 Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety  
Use of growth hormone for appetite suppression or satiety induction
US20140377353 PHARMACEUTICAL PRODUCT TO INDUCE ENDOGENOUS EXACERBATED RELEASE OF GUT HORMONES PYY AND GLP1 WITH THERAPEUTIC EFFECT ON OBESITY AND TYPE 2 DIABETES MELLITUS  
The present invention concerns a pharmaceutical product to induce endogenous exacerbated release of gut hormones, pyy and glp1, with therapeutic effect on obesity and type 2 diabetes mellitus. In...
US20150258208 PEGYLATED OXM VARIANTS  
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or...
US20150119320 PEGYLATED OXM VARIANTS  
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or...
US20140234449 APPETITE REGULATING DIETARY SUPPLEMENT  
A dietary supplement for regulating the appetite of an individual is described. The dietary supplement comprises at least one mechanical satiety regulator, and at least one chemical satiety...
US20130004601 APPETITE REGULATING DIETARY SUPPLEMENT  
A dietary supplement for regulating the appetite of an individual is described. The dietary supplement comprises at least one mechanical satiety regulator, and at least one chemical satiety...
US20150250753 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF  
Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents,...
US20110245159 Salts, Solvates and Pharmaceutical Compositions of Macrocyclic Ghrelin Receptor Agonists and Methods of Using the Same  
The present invention provides novel salts and solvates of macrocyclic compounds that bind to and/or are functional agonists of the ghrelin (growth hormone secretagogue) receptor. The invention...
US20120066775 Stresscopins and their Uses  
The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor....
US20130331315 Protein Hydrolysate Compositions Having Enhanced CCK and GLP-1 Releasing Activity  
The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) and/or giuoagon-like peptide-1 (GLP-1) releasing activity and food forms incorporating the...
US20050287226 High potency clinical anti-craving treatment and method of use  
A practical high potency anti-craving medication is disclosed which comprises three components: an amino-acid component, a vitamin component, and a mineral component, wherein each component is...
US20120040893 MODIFICATION OF FEEDING BEHAVIOUR  
Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist...
US20110257087 Protein Hydrolysate Compositions Having Enhanced CCK Releasing Activity  
The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) releasing activity that can be used to promote satiety.
US20140349922 LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS  
Pegylated and reverse pegylated GLP-1/Glucaron receptor agonists including pharmaceutical compositions comprising the same and methods of using the same are disclosed.
US20070149442 Non-hygroscopic compositions of enterostatin  
The present invention provides pharmaceutical compositions of enterostatin that can display advantageous hygroscopicity, advantageous stability, or both. The pharmaceutical compositions of...
US20150051140 MODIFICATION OF FEEDING BEHAVIOR  
Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist...
US20070082844 Regulation of food preference using GLP-1 agonists  
GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono-and di-saccharides together constitute a large proportion of...

Matches 1 - 50 out of 181 1 2 3 4 >